0001683168-21-003479.txt : 20210812 0001683168-21-003479.hdr.sgml : 20210812 20210812171024 ACCESSION NUMBER: 0001683168-21-003479 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210812 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210812 DATE AS OF CHANGE: 20210812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Phio Pharmaceuticals Corp. CENTRAL INDEX KEY: 0001533040 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36304 FILM NUMBER: 211168645 BUSINESS ADDRESS: STREET 1: 257 SIMARANO DRIVE STREET 2: SUITE 101 CITY: MARLBOROUGH STATE: MA ZIP: 01752 BUSINESS PHONE: (508) 767-3861 MAIL ADDRESS: STREET 1: 257 SIMARANO DRIVE STREET 2: SUITE 101 CITY: MARLBOROUGH STATE: MA ZIP: 01752 FORMER COMPANY: FORMER CONFORMED NAME: RXi Pharmaceuticals Corp DATE OF NAME CHANGE: 20111019 8-K 1 phio_i8k.htm FORM 8-K
0001533040 false 0001533040 2021-08-12 2021-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): August 12, 2021

 

PHIO PHARMACEUTICALS CORP.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36304   45-3215903

(State or other jurisdiction

of incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

257 Simarano Drive, Suite 101

Marlborough, Massachusetts 01752

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (508) 767-3861

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class of securities: Trading Symbol(s): Name of exchange on which registered:
Common Stock, par value $0.0001 PHIO The NASDAQ Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

   

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 12, 2021, Phio Pharmaceuticals Corp. reported its financial results for the period ended June 30, 2021. A copy of the press released is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”).

 

The information in this Item 2.02 and attached as Exhibit 99.1 to this Report will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

     
Exhibit No.   Description
99.1   Press release dated August 12, 2021.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

        PHIO PHARMACEUTICALS CORP.
         
       
Date: August 12, 2021       By:   /s/ Gerrit Dispersyn
           

Gerrit Dispersyn

President and Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

 

EX-99.1 2 phio_ex9901.htm PRESS RELEASE

Exhibit 99.1

 

Phio Pharmaceuticals Reports Second Quarter 2021

Financial Results and Provides Business Update

 

Marlborough, Mass., August 12, 2021/PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended June 30, 2021 and provided a business update.

 

“The first half of 2021 was just the start of what promises to be an exciting period in our development of the INTASYL™ enabled immunotherapy compounds across our pipeline. Over the past several months, we have generated positive new preclinical data from different studies that support the initiation of two first-in-human studies of our lead asset PH-762, an INTASYL compound that targets the checkpoint protein PD-1, in cancer patients. Looking ahead, we are finalizing the studies required for the regulatory submissions for each program and expect to be in a position to initiate both studies in the first half of 2022,” said Dr. Gerrit Dispersyn, President and CEO of Phio. “Overall, we are very excited by the overwhelmingly positive data generated by our pipeline of INTASYL based product candidates. This data shows that the INTASYL platform is a valuable alternative to other direct therapeutic approaches, but can also be used to improve cell based immunotherapy products.”

 

Quarter in Review and Recent Corporate Updates

 

  · Presented a continuous stream of positive data from preclinical studies exploring the flexibility and application of INTASYL in the field of immuno-oncology at leading scientific conferences held during the second quarter of 2021:

  Announced positive new data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting that provide further evidence on the utility of the INTASYL self-delivering RNAi therapy platform to target multiple proteins and provide evidence of the synergy of the Company's pipeline products in the field of immuno-oncology. These in vivo data showed that INTASYL specifically dual-targeting BRD4 and PD-1 elicited complete tumor responses in an in vivo hepatoma model, and significantly outperformed the efficacy of small molecule and antibody treatments towards the same targets.
  Announced positive in vivo data at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) showing that PH-762 can reprogram HER2-targeted CAR-T cells (HER2CART) and significantly enhance their antitumor efficacy in solid tumors, compared to untreated HER2CART cells.
  Announced new in vivo data at the American Association for Cancer Research (AACR) Annual Meeting 2021 showing that intratumoral (IT) treatment with PD-1 targeting INTASYL (mPH-762) inhibits tumor growth in a dose dependent fashion in both PD-1 responsive and refractory models.

 

 

 

 1 

 

 

Upcoming Pipeline Milestones

 

·Expect to initiate a first-in-human clinical study on the use of PH-762 using direct drug therapy (IT) administration for patients with advanced melanoma in the first quarter of 2022.
·Expect to initiate a first-in-human clinical study on the use of PH-762 and tumor infiltrating lymphocytes (TILs) in adoptive cell therapy (ACT) in patients with advanced melanoma in the second quarter of 2022.
·Additional data publications on the Company’s pipeline programs.

 

Financial Results

 

Cash Position

 

At June 30, 2021, the Company had cash of $29.4 million as compared with $14.2 million at December 31, 2020. The Company expects its current cash will be sufficient to fund currently planned operations to the second quarter of 2023.

 

Research and Development Expenses

 

Research and development expenses were approximately $1.7 million for the quarter ended June 30, 2021, compared to approximately $0.8 million for the quarter ended June 30, 2020. The increase is primarily due to manufacturing costs and fees for the required preclinical studies in support of the Company’s planned clinical trials for PH-762 as compared to the same period in the prior year. The Company expects its research and development expenses to continue to increase in support of, and as the Company commences its clinical trial activities with PH-762.

 

General and Administrative Expenses

 

General and administrative expenses were approximately $1.0 million for the quarter ended June 30, 2021, compared to approximately $0.9 million for the quarter ended June 30, 2020. The increase is primarily due to an increase in stock-based compensation expense as no equity awards were granted in the prior year period.

 

Net Loss

 

Net loss was $2.7 million, or $0.20 per share, for the quarter ended June 30, 2021, compared with $1.7 million, or $0.34 per share, for the quarter ended June 30, 2020. The increase in net loss was primarily attributable to the increase in research and development expenses related to the Company’s preclinical activities in preparation for the start of its clinical trials with PH-762, as described above. The change in net loss per share was primarily due to an increase in the number of shares outstanding as a result of the Company’s capital raise activities as compared to the prior year period.

 

About Phio Pharmaceuticals Corp.

 

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.

 

 

 

 

 2 

 

 

Forward Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “intends,” “believes,” “anticipates,” “indicates,” “plans,” “expects,” “suggests,” “may,” “would,” “should,” “potential,” “designed to,” “will,” “ongoing,” “estimate,” “forecast,” “target,” “predict,” “could” and similar references, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by the ongoing coronavirus pandemic, the development of our product candidates, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, results from our preclinical and clinical activities, the timing or likelihood of regulatory filings and approvals, our ability to manufacture and supply our product candidates for clinical activities and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

 

Contact Phio Pharmaceuticals Corp.
ir@phiopharma.com

 

Investor Contact

Ashley R. Robinson 
LifeSci Advisors

arr@lifesciadvisors.com

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

 

 

PHIO PHARMACEUTICALS CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except share and per share data)

(Unaudited)

 

   Three Months Ended
June 30,
   Six Months Ended
June 30,
 
   2021   2020   2021   2020 
Operating expenses:                    
Research and development  $1,663   $779   $4,284   $1,997 
General and administrative   1,021    890    2,038    2,028 
Total operating expenses   2,684    1,669    6,322    4,025 
Operating loss   (2,684)   (1,669)   (6,322)   (4,025)
Total other (expense) income   (3)   (3)   228    2 
Net loss  $(2,687)  $(1,672)  $(6,094)  $(4,023)
Net loss per share: Basic and diluted  $(0.20)  $(0.34)  $(0.50)  $(1.19)
Weighted average shares outstanding: Basic and diluted   13,534,389    4,966,047    12,115,276    3,378,233 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 4 

 

 

PHIO PHARMACEUTICALS CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands)

(Unaudited)

 

 

 

  

June 30,

2021

   December 31,
2020
 
ASSETS          
Cash  $29,425   $14,244 
Restricted cash   50    50 
Prepaid expenses and other current assets   1,680    870 
Right of use asset, net   342    400 
Property and equipment, net   142    157 
Other assets   18    18 
Total assets  $31,657   $15,739 
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Accounts payable  $348   $728 
Accrued expenses and other current liabilities   2,110    1,352 
Lease liability, current   120    116 
Lease liability, net of current portion   234    295 
Long-term debt       231 
Total stockholders’ equity   28,845    13,017 
Total liabilities and stockholders’ equity  $31,657   $15,739 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 5 

 

GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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end EX-101.SCH 4 phio-20210812.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 phio-20210812_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 phio-20210812_pre.xml XBRL PRESENTATION FILE XML 7 phio_i8k_htm.xml IDEA: XBRL DOCUMENT 0001533040 2021-08-12 2021-08-12 iso4217:USD shares iso4217:USD shares 0001533040 false 8-K 2021-08-12 PHIO PHARMACEUTICALS CORP. DE 001-36304 45-3215903 257 Simarano Drive Suite 101 Marlborough MA 01752 (508) 767-3861 false false false false Common Stock, par value $0.0001 PHIO NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Aug. 12, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 12, 2021
Entity File Number 001-36304
Entity Registrant Name PHIO PHARMACEUTICALS CORP.
Entity Central Index Key 0001533040
Entity Tax Identification Number 45-3215903
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 257 Simarano Drive
Entity Address, Address Line Two Suite 101
Entity Address, City or Town Marlborough
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01752
City Area Code (508)
Local Phone Number 767-3861
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001
Trading Symbol PHIO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://phiopharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports phio_i8k.htm phio-20210812.xsd phio-20210812_lab.xml phio-20210812_pre.xml phio_ex9901.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "phio_i8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "phio_i8k.htm" ] }, "labelLink": { "local": [ "phio-20210812_lab.xml" ] }, "presentationLink": { "local": [ "phio-20210812_pre.xml" ] }, "schema": { "local": [ "phio-20210812.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "PHIO", "nsuri": "http://phiopharma.com/20210812", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "phio_i8k.htm", "contextRef": "From2021-08-12to2021-08-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://phiopharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "phio_i8k.htm", "contextRef": "From2021-08-12to2021-08-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://phiopharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001683168-21-003479-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-21-003479-xbrl.zip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end